Work

CRC-403: A Phase 1/2 Study of bbT369, a Dual CD79a and CD20 Targeting CAR T Cell Drug Product with a Gene Edit, in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)

Year: 2022

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2022-162604

Authors: Frederick L. Locke, David B. Miklos, Michael Tees, Tina Bees, Aojun Li, Anna Truppel-Hartmann, Ian W. Flinn

Institutions: Moffitt Cancer Center, Stanford University, Colorado Blood Cancer Institute, Sarah Cannon, Tennessee Oncology

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310126140

Cites:

Cited by: 7

Related to: 10